Off-Label Communications: Near-Term ‘Seismic Shift’ In FDA Oversight Unlikely
Executive Summary
It’s not realistic to expect sudden changes in US agency’s regulation of medical product communications to healthcare providers and payers given the other pressing issues facing new Commissioner Scott Gottlieb, Medical Information Working Group’s Klasmeier says.
You may also be interested in...
Pfizer Skeptical About Value-Based Contracting In Current Environment
'We have about 18 different projects underway but we've achieved' only one value-based deal, Pfizer CEO Ian Read says. 'The risks and incentives have to be with the providers. … That's how you get the best health care.'
Postmarketing Studies On Abuse-Deterrent Opioids Could Get New Look
Data sources and methodologies to evaluate real-world effects of abuse-deterrent formulations will be focus of US FDA public meeting in July; value and feasibility of assessing the public health effects of such products more broadly is up for discussion.
Unapproved Uses Bill May Eventually Pass, But Would Likely Need Additional Safeguards
Off-label communication amendments tabled at House markup of user fee legislation after Democrats object; the two sides agreed to discuss the issue further down the road.